172 related articles for article (PubMed ID: 19464527)
1. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
Front Immunol; 2018; 9():335. PubMed ID: 29563911
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
[TBL] [Abstract][Full Text] [Related]
4. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
Nébié I; Edwards NJ; Tiono AB; Ewer KJ; Sanou GS; Soulama I; Sanon S; Diarra A; Yaro JB; Kangoye D; Imoukhuede EB; Hill AV; Sirima SB
Clin Vaccine Immunol; 2014 Jun; 21(6):901-3. PubMed ID: 24739980
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
[TBL] [Abstract][Full Text] [Related]
6. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.
Santra S; Sun Y; Korioth-Schmitz B; Fitzgerald J; Charbonneau C; Santos G; Seaman MS; Ratcliffe SJ; Montefiori DC; Nabel GJ; Ertl HC; Letvin NL
Vaccine; 2009 Sep; 27(42):5837-45. PubMed ID: 19660588
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.
Zhi Y; Figueredo J; Kobinger GP; Hagan H; Calcedo R; Miller JR; Gao G; Wilson JM
Hum Gene Ther; 2006 May; 17(5):500-6. PubMed ID: 16716107
[TBL] [Abstract][Full Text] [Related]
9. New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.
Limbach K; Stefaniak M; Chen P; Patterson NB; Liao G; Weng S; Krepkiy S; Ekberg G; Torano H; Ettyreddy D; Gowda K; Sonawane S; Belmonte A; Abot E; Sedegah M; Hollingdale MR; Moormann A; Vulule J; Villasante E; Richie TL; Brough DE; Bruder JT
Malar J; 2017 Jul; 16(1):263. PubMed ID: 28673287
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
[TBL] [Abstract][Full Text] [Related]
11. Generation of an adenoviral vaccine vector based on simian adenovirus 21.
Roy S; Zhi Y; Kobinger GP; Figueredo J; Calcedo R; Miller JR; Feldmann H; Wilson JM
J Gen Virol; 2006 Sep; 87(Pt 9):2477-2485. PubMed ID: 16894185
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
Fonseca JA; McCaffery JN; Caceres J; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2018 May; 36(20):2799-2808. PubMed ID: 29657070
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.
Ogwang C; Kimani D; Edwards NJ; Roberts R; Mwacharo J; Bowyer G; Bliss C; Hodgson SH; Njuguna P; Viebig NK; Nicosia A; Gitau E; Douglas S; Illingworth J; Marsh K; Lawrie A; Imoukhuede EB; Ewer K; Urban BC; Hill AVS; Bejon P;
Sci Transl Med; 2015 May; 7(286):286re5. PubMed ID: 25947165
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
19. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
Fitzgerald JC; Gao GP; Reyes-Sandoval A; Pavlakis GN; Xiang ZQ; Wlazlo AP; Giles-Davis W; Wilson JM; Ertl HC
J Immunol; 2003 Feb; 170(3):1416-22. PubMed ID: 12538702
[TBL] [Abstract][Full Text] [Related]
20. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
